At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled, Parallel Group, 4-week Study to Evaluate the Efficacy of Empagliflozin (10 mg and 25 mg Administered Orally Once Daily) in Postprandial Glucose and 24-hour Glucose Variability in Japanese Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control
In Brief
A Phase 3 clinical trial evaluating Placebo and Empagliflozin for Diabetes Mellitus, Type 2. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
To evaluate the efficacy of empagliflozin administered orally once daily in postprandial glucose and 24-hour glycaemic variability compared to placebo given for 4 weeks as mono-therapy in Japanese patients with type 2 diabetes mellitus with insufficient glycaemic control on no antidiabetic treatment.
Study Details
Timeline
Interventions
Placebo tablet matching Empagliflozin low dose
Empagliflozin low dose
Placebo tablet matching Empagliflozin high dose
Placebo tablet matching Empagliflozin low dose
Empagliflozin high dose tablet once daily
Placebo tablet matching Empagliflozin high dose